PND12: TREATMENT AND HEALTH-CARE SATISFACTION AMONG PEOPLE WITH MIGRAINE HEADACHES  by Mackell, JA & McDonnell, DD
522 Abstracts
PND12
TREATMENT AND HEALTH-CARE 
SATISFACTION AMONG PEOPLE WITH 
MIGRAINE HEADACHES
Mackell JA1, McDonnell DD2
1Pfizer Pharmaceuticals Group, Pfizer, Inc, New York, NY, USA; 
2Consumer Health Sciences, Princeton, NJ, USA
OBJECTIVES: Satisfaction with health care has been
linked to positive health-related behavior and improved
efficacy of care. Among people with migraine headaches,
there are unmet needs for appropriate diagnosis, medica-
tions, and care. This analysis will therefore explore
whether treatment of migraines with prescription medi-
cations improves health-care satisfaction.
METHODS: Data were obtained from a spring 2000 sur-
vey. A total of 21,986 (56%) questionnaires were re-
turned from an initial mailing to 39,491 US adults whose
names were purchased from a large marketing company.
The 12-page survey covered a range of health topics in-
cluding opinions, health history, and treatments. Respon-
dents were asked how satisfied they were with their
health care on a six-point scale from “strongly disagree”
(1) to “strongly agree” (6). Migraine status was assessed
by asking whether respondents had migraines (yes/no), if
these were diagnosed by a doctor (yes/no), and if they
used a prescription drug (Rx) to treat them (yes/no). Se-
verity was self-reported as mild, moderate, or severe.
RESULTS: A total of 4,069 people (19%) reported hav-
ing migraines. Of those, 65% (n  2,605) were diag-
nosed and 42% (n  1,090) of those reported currently
using an Rx. Compared to those without migraines, peo-
ple with migraines were less likely to be satisfied with
their health care (59% vs. 51%, p  .001). However,
those treating their migraines with prescription medica-
tion were more likely to be satisfied than those who were
not taking an Rx (59% vs. 50%, p  .001). These bivari-
ate associations remained after controlling for potential
confounders (health-care resource use, overall physical
and mental health), when comparing migraineurs to non-
migraineurs (B  .07, p  0.026) as well as diagnosed
vs. undiagnosed (B  .25, p  .001) and people with at
least moderately severe conditions (B  .26, p  .001).
CONCLUSIONS: People who are successfully treated
have higher health-care satisfaction. Physicians should
therefore work with patients to find a medication that is
effective for their patients’ spectrum of migraine symp-
toms.
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OBJECTIVES: Migraines affect an estimated 11 million
people in the US. Using self-reports, the effects on quality
of life are comparable to, if not worse than, angina, ar-
thritis, or depression. This analysis explores whether
treatment with prescription medication improves mi-
graine sufferers’ quality of life.
METHODS: Data were obtained from a survey conducted
in spring 2000. A total of 21,986 questionnaires were re-
turned (56%) from a mailing to 39,491 US adults whose
names were purchased from a large marketing company.
The 12-pages covered health history, opinions, and treat-
ments. Quality of life was evaluated using the mental score
of the SF-12, a generic measure of health status (Ware, et
al 1996). The mean for US adults is 50; higher scores indi-
cate better well being. Migraine status was assessed by ask-
ing whether respondents had migraines (yes/no), if these
were diagnosed by a doctor (yes/no), and if they used a
prescription drug (Rx) to treat them (yes/no). Severity was
self-reported as mild, moderate, or severe.
RESULTS: A total of 4,069 people (19%) reported mi-
graines. Of these, 65% (n  2,605) were diagnosed and
42% (n  1,090) of these used prescription medications. In
bivariate analyses, those taking an Rx had slightly higher
quality of life than those not taking a drug (46.6 vs. 45.9,
p  .164), even though Rx users had more severe migraines
and severe migraine sufferers tended to have lower quality
of life. Since the relationship between quality of life and Rx
use was confounded by severity, a linear regression model
was run to control for potential confounders (severity, age,
comorbidities, migraine frequency). In this model, those tak-
ing an Rx had higher quality of life than those not taking a
drug (B  1.08, p  0.020).
CONCLUSIONS: Migraine sufferers who are success-
fully treated with prescription medications have higher
quality of life than those not taking medication. Physi-
cians should work with patients to find a medication that
targets their migraine-specific symptoms.
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QUALITY OF LIFE OF WOMEN SUFFERING 
FROM MENSTRUAL MIGRAINE AND 
RELATIONSHIP WITH MOOD
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OBJECTIVE: A lot of women suffer from menstrual mi-
graine. This affects quality of life (QoL) and mood. Our sur-
vey: a) evaluated the relationship between menstrual mi-
graine and mood; b) measured the QoL of a sample of
women; c) compared it with the norm for an Italian female.
METHODS: This was a cross-sectional, multicenter survey.
Eligible patients (pts) were those suffering from menstrual
migraine (range: 2 to 3 days around the first day of
menstruation), and receiving an anti-migraine treatment for
4 weeks at least. Doctors reported socio-demographic, clini-
cal and therapeutic data, measured mood of pts by the
Hamilton Depression rating scale (HDRS), and adminis-
tered the SF-36 questionnaire to pts. Demographic and clin-
ical details were summarized by descriptive statistics. HDRS
scores and SF-36 were calculated according to author’s in-
